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Conservative management of Charcot foot neuroarthropathy remains efficacious for certain clinical scenarios.
Treatment of the patient should take into account the stage of the Charcot neuroarthopathy, site(s) of
involvement, presence or absence of ulceration, presence or absence of infection, overall medical status, and
level of compliance. The authors present an overview of evidence-based non-operative treatment for diabetic
Charcot neuroarthropathy with an emphasis on the most recent developments in therapy.
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T
he association between Charcot neuroarthropathy
(CN) and diabetes mellitus was first described by
Jordan in 1936 (1). Since that time numerous
treatment protocols have been proposed for this poten-
tially devastating condition. Early diagnosis and swift
care are the keys to reducing amputation risk in this
patient population. Conservative management remains
efficacious for certain clinical scenarios. Treatment of the
patient should take into account the stage of CN, site(s)
of involvement, presence or absence of ulceration, pre-
sence or absence of infection, overall medical status, and
level of compliance. The most commonly used classifica-
tion is the three-staged system described by Eichenholtz:
Stage I is the developmental or acute phase, Stage II is
the coalescent or quiescent phase, and Stage III is the
consolidation or reconstruction and reconstitution phase
(2). Involvement of the midfoot is most common in
the diabetic population and this site tends to be more
amenable to conservative options versus hindfoot or
ankle CN. Generally, conservative care for the CN foot
and ankle has been recommended for the following
scenarios: joints in the acute phase, deformities that are
clinically stable and that do not compromise the soft
tissue envelope, stable deformities without soft tissue or
bone infection, patients who do not have adequate
arterial perfusion to support surgical reconstruction,
and those patients who are extremely high risk for
anesthesia and surgical intervention due to the presence
of multiple severe comorbid conditions. The authors
present an overview of evidence-based non-operative
treatment for CN with an emphasis on the most recent
developments in therapy.
Immobilization and mechanical protection
The initial stage of CN is typically characterized by
clinical erythema, warmth and swelling of the extremity,
along with radiographic findings of bone fragmentation
and debris with joint disruption and dislocation. Im-
mobilization at this point is crucial to the prevention of
further collapse and permanent deformity. Prolonged
non-weight-bearing cast immobilization is typically ad-
vocated for at least 3 months to allow for resolution of
acute inflammation and radiographic consolidation of
fragmented bone. The total contact cast (TCC) has
established an important role in the treatment of Stage
I CN. In 2000, a survey of US orthopedic surgeons
revealed that 80% of respondents used the TCC as their
first-line therapy (3). This study pointed out, however,
that there is some controversy regarding the necessity for
complete non-weight bearing. The traditional TCC can
be modified with a rigid rocker sole or a cast shoe to
facilitate pressure reduction during ambulation. Many
practitioners allow weight bearing in the TCC since most
insensate patients will inevitably bear some weight on the
affected limb during treatment. Proponents of the weight
bearing TCC also cite the increased load stress on the
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quences. A prospective study on 10 patients by Pinzur
et al. (4) demonstrated successful treatment of Stage I CN
using the weight bearing TCC with an average return to
depth inlay shoes and custom orthoses in 9.2 weeks.
Sinacore (5) showed longer healing times with the TCC
when the site of CN involvement was at the ankle,
hindfoot, or midfoot compared to that of the forefoot.
Numerous fabrications of the TCC have been developed
to help decrease cost of materials and length of time for
application.
Case report
The authors have successfully used the TCC for patients
in which surgical reconstruction was not indicated. One
such patient was a 46-year-old female who had presented
to our outpatient clinic with new onset swelling and
redness of her left foot. She reported sustaining a twisting
injury about 2 weeks prior but felt no pain at the time.
She had noticed progressive difficulty in bearing weight
to the affected foot. Her medical history was positive for
poorly controlled diabetes mellitus, hypertension, and
hyperlipidemia. She denied previous foot or ankle injuries
or ulcerations, but admitted to numbness in both feet for
the past few years. On physical examination, her vital
signs were stable. Her left foot demonstrated strongly
palpable pulses and non-pitting edema circumferentially
about the midfoot and forefoot with erythema that
dissipated upon elevation of the limb. She had no open
wounds or tenting of the skin; however, there was notably
increased temperature of the left foot compared to the
contralateral side. Both feet revealed absent protective
sensation when tested by Semmes-Weinstein 5.0 g mono-
filament. Radiographs of the left foot and ankle showed
marked soft tissue swelling and subtle diastasis between
the first and second metatarsal bases and between the
medial and intermediate cuneiforms. Based on medical
history, traumatic incident in the presence of peripheral
neuropathy, as well as clinical and radiographic evidence,
we diagnosed the patient with acute phase CN of the
midfoot. She was immobilized in a non-weight-bearing
TCC for 12 weeks with cast changes, clinical evaluation,
and serial radiographs at 2-week intervals. Once we
noticed resolution of edema, erythema, and warmth to
the foot, along with radiographic evidence of coalescence
at the midfoot, she was gradually transitioned to custom
molded extra depth shoes with multidensity insoles and a
double-upright ankle-foot-orthotic brace. Thereafter, she
was able to regain full ambulatory status with a stable,
plantigrade foot without preulcerative lesions or infection
without complications (Figs 1 and 2).
In contrast to the TCC, the use of the patellar tendon-
bearing brace (PTB) can help off-set the increased load
on the contralateral limb. This brace has also been used
in the treatment of diabetic foot ulcers. Saltzman et al. (6)
established that the PTB reduced load transmission to
the hindfoot but not at the midfoot or forefoot, therefore
cautioned the importance of using it accordingly. The
PTB has also been recommended for prophylactic
protection of the contralateral limb during immobiliza-
tion of the involved foot and/or ankle. Clohisy and
Thompson (7) found evidence of CN on the contralateral
limb after an average of 4.5 months in such cases. The
Charcot Restraint Orthotic Walker (CROW) is a long-
term custom device that essentially serves as a removable
TCC (8). The device is a custom molded, full-foot
enclosure consisting of a polypropylene outer shell,
rocker sole, and plastizote padded inner lining (Fig. 3).
The CROW was initially developed for use in Stage I CN;
however, more recently it is also proving useful in Stage 3
to maintain foot and ankle alignment. Koller et al. (9)
advocate the CROW for patients following surgical
reconstruction, specifically after external fixation proce-
dures. It is important to note that design and efficacy of
the removable walker device relies heavily on patient
compliance.
Once the CN has progressed to Stage 3, commercially
available orthopedic footwear is recommended. Forefoot
and midfoot deformities can be accommodated by full-
length multidensity inserts and extra depth shoes. Severe
midfoot deformities require the fabrication of custom
shoes to accommodate the misshapen foot. Mild rearfoot
deformities may tolerate a high-top custom-molded shoe
with a full-length orthotic device. Moderately unstable
ankle deformities may benefit from a solid ankle foot
orthoses and a therapeutic shoe. Severely unstable rear-
foot deformities require a PTB brace in a custom shoe.
Similar recommendations exist for use of custom foot-
wear and/or bracing following surgical reconstructions of
CN. Further studies are needed with regard to these
modalities as there are currently no randomized con-
trolled trials available for the application of TCC, CROW,
PTB, or orthopedic bracing and footwear in CN patients.
Bone growth stimulation
First developed in the 1950s and commonly used in
fracture care, electrical bone stimulation has become
popular in the treatment of CN due to its ability to
stimulate osteogenesis in the early stages of the disease
(10). Fitzsimmons and Baylink (11) performed cell
culture studies showing that low-energy electromagnetic
fields stimulate insulin-like growth factor II, which
increases calcium flux and is associated with increased
rate of bone cell proliferation. Hanft et al. (12) used
combined magnetic field bone stimulation on patients
with Stage I CN for 30 min daily in addition to off-
loading and demonstrated a statistically significant
reduction in time to consolidation when compared to
control subjects (11 weeks vs. 23.8 control). Additionally,
Strauss and Gonya (13) showed accelerated bone healing
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subtalar and ankle joint arthrodesis. Both implantable
and external devices are available. Surgeons have used
bone stimulators in conjunction with other reconstructive
procedures, however, the magnitude of their benefit is yet
unknown (14).
Drug therapy
Due to bone mineral density alterations in CN patients
manifested by localized osteopenic changes, bisphospho-
nates have been tested for their benefit with off-loading in
Stage I. Bisphosphonates are pyrophosphate analogs that
inhibit osteoclastic bone resorption and are commonly
used in treatment of conditions characterized by abnor-
mal bone turnover. Pamidronate is the most commonly
used and acts by attaching onto hydroxyapatite crystals
in newly synthesized bone matrix, blocking access of
osteoclast precursors to this matrix. Jude et al. (15)
performed a randomized double-blind placebo-controlled
39 patients with active Charcot in which a single 90 mg
pamidronate infusion was administered and standard off-
loading provided while foot temperatures, symptoms, and
bone turnover markers were measured over 1-year. There
was a statistically significant reduction in bone turnover,
symptoms, and disease activity. Similarly, Pitocco et al.
(16) showed significant reduction in bone resorption
markers with the use of another bisphosphonate alen-
dronate and noted clinical improvements in the CN foot
at 6 months.
Briefly, activation of osteoclasts involved in osteolysis
is accomplished by the nuclear transcription factor NF-
kB. The expression of NF-kB is induced by the cytokine
RANK-L, which is accompanied by increased produc-
tion of osteoprotegerin (OPG). The RANK-L/OPG
system’s theoretical role in osteopenia associated with
diabetic neuropathy led to the development and use of
intranasal salmon calcitonin for treatment of acute CN.
A randomized controlled trial by Bem et al. (17) was
performed on 32 acute CN patients administered 200 IU
daily, showing reduction in markers of bone turnover as
well as a decreased time to healing. This therapy has
shown fewer complications compared to bisphosphonate
use. Potential therapeutic agents that also have a direct
effect on the RANK-L/OPG system in addition to
Fig. 1. Initial clinical presentation of an acute Charcot foot neuroarthropathy at the midfoot level with radiographic bony
fragmentation and minimal collapse (AC). Patient had no history of any open wounds or osteomyelitis and was eventually treated with
strict immobilization, total contact casting, and progression into diabetic custom molded shoe gear and bracing. Final radiographic
views at 1-year follow-up showing bony consolidation and no further progression of the deformity (DF).
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(TNF-a), glucocorticoids and non-steroidal anti-inflam-
matories. Jeffcoate (18) has also mentioned other future
options including synthetic OPG and RANK-L antago-
nists and other inhibitors of NF-kB and TNF-a.
Conclusion
Conservative options continue to evolve in their indica-
tions for the treatment of the CN foot and ankle.
The modalities discussed within this article provide a
wide variety of options; yet, a further higher level of
evidence studies iswarranted. There is no doubt that there
are specific indications for conservative management
versus surgical. Regardless of the chosen treatment path-
way, all protocols should be specific to the patient based
on their lower extremity pathology, overall medical status,
and ability to comply with the given therapy.
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